Ibcasertib is under clinical development by Shenzhen Chipscreen Biosciences and currently in Phase II for Graft Versus Host Disease (GVHD). According to GlobalData, Phase II drugs for Graft Versus Host Disease (GVHD) have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ibcasertib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ibcasertib overview
CS-2164 (Chiauranib) is under development for the treatment of small-cell lung cancer, fallopian tube cancer, relapsed and refractory non-Hodgkin lymphoma, epithelial ovarian cancer, liver cancer, ovarian cancer, colorectal cancer, kidney cancer, gastric cancer, lung cancer including non-small cell lung cancer, gastrointestinal stromal tumor, small-cell lung cancer, non-small cell lung carcinoma, neuroendocrine tumors, hepatocellular carcinoma, breast cancer, peritoneal carcinoma, soft tissue sarcoma, triple-negative breast cancer (TNBC), HER2- Breast Cancer and other solid tumors and soft tissue sarcomas including liposarcoma, leiomyosarcoma, synovial sarcoma, undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma, fibrosarcoma sarcoma, clear cell sarcoma, angiosarcoma, epithelioid sarcoma, malignant peripheral nerve sheath tumor, undifferentiated sarcoma, Ewing's sarcoma, rhabdomyosarcoma, dermatofibrosarcoma protuberanoma, myofibroblastic sarcoma, malignant solitary fibroma, radiotherapy posterior sarcoma, acinar soft tissue sarcoma, well-differentiated/dedifferentiated liposarcoma, graft versus host disease, pancreatic cancer. It is administered through oral route in the form of capsule. It acts by targeting Aurora B, VEGFR, PDGFR, c-Kit and CSF1R. The drug candidate is being developed based on chemical genomics-based discovery platform.
It was also under development for the treatment of diffuse large B-cell lymphoma and peripheral T-cell lymphoma, renal cell carcinoma.
Shenzhen Chipscreen Biosciences overview
Shenzhen Chipscreen Biosciences (Chipscreen) is a biotechnology company. The company develops drugs in therapeutic areas of malignant tumors, metabolic diseases, autoimmune diseases, central nervous system diseases, and antivirals. Its product pipeline includes Chidamide, Siglitastat sodium, Cioroni, CS12192 and others. Its chidamide product is a novel subtype-selective HDAC inhibitor functioning as an epigenetic modulator for the treatment of various hematological and solid cancers. Chipscreen offers protocol design, clinical research and monitoring, and data analysis and management services. The company provides clinical and preclinical stage programs in various therapeutic areas. It operates in China. Chipscreen is headquartered in Shenzhen, Guangdong, China.
For a complete picture of Ibcasertib’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
